- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00550771
Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)
Randomized Phase II Multinational Trial to Evaluate the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy in Patients With HER2-positive Breast Cancer: Caelyx + Cyclophosphamide + Trastuzumab (C+C+H) or Doxorubicin + Cyclophosphamide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H) BACH
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Subjects with operable, node-positive or high-risk node-negative (see #3 below) HER2-positive breast carcinoma are eligible for the study, provided they satisfy the following criteria.
- Subjects must demonstrate willingness to and be able to participate in the study and to adhere to dose and visit schedules
- Subjects must be of female gender and >= 18 years of age
Subjects must have been diagnosed with operable, histologically confirmed adenocarcinoma of the breast with no clinical or radiological evidence of metastatic disease but with otherwise high or intermediate risk tumor characteristics:
- node-positive: T1-3, N1-2, M0 (level of T [tumor involvement], N [lymph node involvement], & M [matastases]) OR
node-negative AND at least one of the following features:
- Tumor >2 cm or
Tumor >1 cm and
- Negative estrogen receptor/progesterone receptor (ER/PR) or
- Malignancy Grade 2-3 or
- Presence of peritumoral vascular invasion or
- Age <35 years
- HER2-positive by fluorescence in situ hybridization (FISH)(with gene amplification) or 3+ using
immunohistochemistry
- Subjects must have had complete resection (R0) of the primary tumor and axillary lymph nodes (or must have negative sentinel node[s])
- Baseline left ventricular ejection fraction (LVEF) by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) >=55%
- Easter Cooperative Oncology Group (ECOG)-performance status of 0-1
- Adequate postoperative bone marrow function with neutrophils >=1.5 x 10^9/l, platelets >=100 x 10^9/l and hemoglobin >= lower limit of normal (LLN)
- Adequate renal function: calculated creatinine clearance >=50 ml/min
- Adequate postoperative liver function with a total bilirubin < upper limit of normal (ULN), alkaline phosphatase <2.5 times the ULN and aspartate aminotransferase (AST) <1.5 times the ULN
- Subjects must be free of any clinically relevant disease that would, in the principal investigator's and/or sponsor's opinion, interfere with the conduct of the study or study evaluations
- Subjects of childbearing potential (including women who are less than one year postmenopausal and will be sexually active during the study) must agree to use a medically accepted method of contraception, while receiving protocol-specified medication and for 30 days (or as per local requirements) after stopping the medication or be surgically sterilized prior to screening
- Subjects must be able to provide written informed consent
Exclusion Criteria:
Subject who meets any of the following exclusion criteria will be disqualified from participation in the study:
- Clinical or radiological evidence of metastatic disease
- Prior radiotherapy, chemotherapy or biotherapy for the currently diagnosed breast cancer prior to randomization
- Clinically significant pericardial effusion
Serious cardiac illness including, but not confined to
- history of documented congestive heart failure
- history of any form of cardiomyopathy or active treatment for any form of cardiomyopathy
- history of angina pectoris or documented transmural myocardial infarction, or active angina pectoris requiring medication
- serious ventricular arrhythmias requiring medication or implantable cardioverter-defibrillator (ICD) therapy, uncontrolled supraventricular arrhythmias
- clinically significant valvular disease
- poorly controlled arterial hypertension (systolic blood pressure (BP) >180 mmHg, diastolic BP >100 mmHg)
- Sensory/motor neuropathy > grade 2 as defined by National Cancer Institure - Common Toxicity Criteria (NCI-CTC)
- Pregnancy, or intending to become pregnant during the study
- Nursing (breastfeeding) or intending to be nursing during the study
Any of the following clinical conditions:
- Chronic obstructive pulmonary disease, requiring chronic treatment
- Clinically significant active infections
- A history of a psychological illness of condition, preventing the subject to understand the requirements of the study
- Unstable regulation of diabetes mellitus
- A situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study
- Is on staff, affiliated with, or a family member of the staff personnel directly involved with this study
- Usage of any investigational product within 30 days prior to enrollment
- Participation in any other interventional clinical study involving drug, device or biological. This would not prohibit the patient from participating in a quality of life (QOL), questionnaire, blood collection, or observational study.
- Allergy to or sensitivity to the study drug or its excipients
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: Doxorubicin Based Regimen
|
doxorubicin 60 mg/m^2 IV push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)
|
Experimenteel: Pegylated Liposomal Doxorubicin (PLD) Based Regimen
|
PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year
Tijdsspanne: 8 cycles of chemotherapy and subsequently one year of planned trastuzumab treatment
|
Cardiac events defined as: Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of >10 percentage points from baseline and to ≤50% LVEF Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of >10 percentage points from baseline and to <50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks. |
8 cycles of chemotherapy and subsequently one year of planned trastuzumab treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During the 8 Cycles of Chemotherapy
Tijdsspanne: During the 8 courses of chemotherapy
|
Cardiac events defined as: Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of >10 percentage points from baseline and to ≤50% LVEF Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of >10 percentage points from baseline and to <50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks. |
During the 8 courses of chemotherapy
|
Number of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During 1 Year of Trastuzumab Therapy
Tijdsspanne: During 1 year of trastuzumab therapy
|
Cardiac events defined as: Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a definite or probable cardiac event, or severe symptomatic HF, concomitant with a left ventricular ejection fraction (LVEF) drop of >10 percentage points from baseline and to ≤50% LVEF Level 2: Asymptomatic systolic dysfunction or mildly symptomatic HF concomitant with an LVEF drop of >10 percentage points from baseline and to <50% LVEF; the LVEF drop was to have been confirmed within 3-4 weeks. |
During 1 year of trastuzumab therapy
|
Number of Participants Who Survived Without Relapse
Tijdsspanne: Approximately 2 years
|
Relapse-free survival would have been determined by Kaplan-Meier method. This was not calculated, since the 2 year follow-up was curtailed. |
Approximately 2 years
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Huidziektes
- Neoplasmata
- Neoplasmata per site
- Borst ziekten
- Borstneoplasmata
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Enzymremmers
- Antireumatische middelen
- Antineoplastische middelen
- Immunosuppressieve middelen
- Immunologische factoren
- Tubuline-modulatoren
- Antimitotische middelen
- Mitose modulatoren
- Antineoplastische middelen, alkylering
- Alkyleringsmiddelen
- Myeloablatieve agonisten
- Antineoplastische middelen, fytogeen
- Topoisomerase II-remmers
- Topoisomeraseremmers
- Antineoplastische middelen, immunologisch
- Antibiotica, antineoplastiek
- Cyclofosfamide
- Paclitaxel
- Trastuzumab
- Albumine-gebonden paclitaxel
- Doxorubicine
- Liposomale doxorubicine
Andere studie-ID-nummers
- P05048
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Borst neoplasma
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University en andere medewerkersVoltooidDe klinische toepassingsgids van Conebeam Breast CTChina
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
Klinische onderzoeken op doxorubicin, cyclophosphamide, paclitaxel, trastuzumab
-
Novartis PharmaceuticalsVoltooidMetastatische of lokaal gevorderde solide tumorenNederland, Spanje, Duitsland, Zwitserland, België
-
Guangdong Provincial People's HospitalOnbekend
-
QuantumLeap Healthcare CollaborativeByondis B.V.IngetrokkenEierstokkanker | Uitgezaaide kanker | Uitgezaaide borstkanker | Blaaskanker | Drievoudige negatieve borstkanker | HER2-positieve borstkanker | Gastro-oesofageaal adenocarcinoom | Ovariumcarcinoom | HER2-positieve maagkanker | Metastatische gastro-intestinale carcinoïde tumor | HER2-positieve uitgezaaide... en andere voorwaardenVerenigde Staten
-
Merrimack PharmaceuticalsVoltooidHER-2 genamplificatieVerenigde Staten
-
Dana-Farber Cancer InstituteJohns Hopkins University; Translational Breast Cancer Research ConsortiumNog niet aan het wervenBorstkanker | HER2-positieve borstkanker | Stadium IV borstkanker | Borstkanker Vrouw | Borstkanker uitgezaaid | Oestrogeenreceptor-positieve borstkankerVerenigde Staten
-
Institut de cancérologie Strasbourg EuropeNog niet aan het werven
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)Voltooid
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)WervingAnatomische fase II borstkanker AJCC v8 | Anatomisch stadium IIA borstkanker AJCC v8 | Anatomisch stadium IIB borstkanker AJCC v8 | Anatomisch stadium IIIA borstkanker AJCC v8 | Prognostische fase II borstkanker AJCC v8 | Prognostische fase IIA borstkanker AJCC v8 | Prognostische fase IIB borstkanker... en andere voorwaardenVerenigde Staten, Puerto Rico
-
Lawson Health Research InstituteThe Ottawa HospitalVoltooid
-
Genentech, Inc.National Cancer Institute (NCI)Voltooid